(Q34528602)

2 August 2017

1 reference

title

Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation (English)

1 reference

2 August 2017

1 reference

Icilio Cavero

1

1 reference

2 August 2017

Jean-Michel Guillon

2

1 reference

2 August 2017

Veronique Ballet

3

1 reference

2 August 2017

Mike Clements

4

1 reference

2 August 2017

Jean-Frédéric Gerbeau

5

1 reference

2 August 2017

Henry Holzgrefe

6

1 reference

2 August 2017

publication date

24 May 2016

1 reference

Journal of Pharmacological and Toxicological Methods

2 August 2017

published in

1 reference

2 August 2017

volume

81

1 reference

2 August 2017

page(s)

21-36

1 reference

Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Assessing proportionality in the proportional odds model for ordinal logistic regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Dispersion of ventricular repolarization and refractory period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

CiPA: Ongoing testing, future qualification procedures, and pending issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Late cardiac sodium current can be assessed using automated patch-clamp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

A computational and experimental study inside microfluidic systems: the role of shear stress and flow recirculation in cell docking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Multielectrode Array (MEA) Assay for Profiling Electrophysiological Drug Effects in Human Stem Cell-Derived Cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Ionic mechanisms of electrophysiological properties and repolarization abnormalities in rabbit Purkinje fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Early identification of hERG liability in drug discovery programs by automated patch clamp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

How to correct the QT interval for the effects of heart rate in clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Recent developments in using mechanistic cardiac modelling for drug safety evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Evolution of strategies to improve preclinical cardiac safety testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Antiarrhythmic properties of ranolazine: A review of the current evidence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Validation of a voltage-sensitive dye (di-4-ANEPPS)-based method for assessing drug-induced delayed repolarisation in beagle dog left ventricular midmyocardial myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

A Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte (hiPSC-CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

L-type Ca2+ channel responses to bay k 8644 in stem cell-derived cardiomyocytes are unusually dependent on holding potential and charge carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Uncertainty and variability in models of the cardiac action potential: Can we build trustworthy models?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Slow delayed rectifier potassium current (IKs) and the repolarization reserve.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Ca²⁺ channel activators reveal differential L-type Ca²⁺ channel pharmacology between native and stem cell-derived cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Drug-Induced Long QT Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Review: Microfluidic applications in metabolomics and metabolic profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Rapid cellular phenotyping of human pluripotent stem cell-derived cardiomyocytes using a genetically encoded fluorescent voltage sensor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Update on the slow delayed rectifier potassium current (I(Ks)): role in modulating cardiac function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Characterization of beta subunit modulation of a rabbit cardiac L-type Ca2+ channel alpha 1 subunit as expressed in mouse L cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: multi-site validation study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Requirement of the calcium channel beta subunit for functional conformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Computational models of ventricular- and atrial-like human induced pluripotent stem cell derived cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Human ex-vivo action potential model for pro-arrhythmia risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

A defined synthetic substrate for serum-free culture of human stem cell derived cardiomyocytes with improved functional maturity identified using combinatorial materials microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

The Rise of CRISPR/Cas for Genome Editing in Stem Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

hERG K(+) channels: structure, function, and clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

A molecular mechanism for adrenergic-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.05.012

10.1016/J.VASCN.2016.05.012

7 January 2021

Identifiers

DOI

1 reference

release_g3sllwqw2fdjlimcbzdb6vn4q4

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g3sllwqw2fdjlimcbzdb6vn4q4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference